{
    "nctId": "NCT02479997",
    "briefTitle": "Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer Patients",
    "officialTitle": "Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer Patients Who Receive Neoadjuvant Therapy(Chemotherapy, Hormonal Therapy, Targeted Therapy); Clinical Study for 130 Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 130,
    "primaryOutcomeMeasure": "Identification rate of sentinel lymphnode biopsy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* breast cancer patients who receive neoadjuvant therapy (chemotherapy,hormonal therapy, targeted therapy)\n* cN1-cN2 or cN3( but must be complete response status)on tumor lymphnode metastasis classification( TNM) after neoadjuvant therapy.\n* ECOG Performance status 0 or 1\n* consented patients with more than 20 years, less than 70 years\n\nExclusion Criteria:\n\n* history of breast cancer\n* early stage breast cancer\n* history of excisional or incisional biopsy or axillary dissection\n* inflammatory breast carcinoma\n* cN3 on tumor lymphnode metastasis classification(TNM)\n* stage 4 breast cancer\n* pregnancy",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}